Want to see FR:VIRP full AI Analyst Report?
Top Page
Virbac SA
(VIRP)
Select Model
Select Model
Rating:69Neutral
Price Target:
€331.00
▲(2.48% Upside)
Action:Reiterated
Date:08/04/26
The score is driven primarily by solid financial fundamentals (steady growth, durable margins, and a conservatively positioned balance sheet), partially offset by only moderate and weakening cash conversion. Technical signals are neutral-to-mildly positive, and valuation appears reasonable but not compelling given the low dividend yield.
Positive Factors
Revenue Growth and Profitability
Accelerating revenue alongside consistently solid margins indicates broadening demand and durable operating performance. Maintaining roughly 10% net margins gives Virbac resources to support research, product development, commercial expansion, and resilience across the next several quarters.
Negative Factors
Moderate Cash Conversion
Healthy reported profits are not converting fully into free cash flow, and the decline from 2024 signals weaker cash quality. Persistent working-capital or investment needs could increase year-to-year cash volatility and limit the funds available for debt reduction, acquisitions, or shareholder returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth and Profitability
Accelerating revenue alongside consistently solid margins indicates broadening demand and durable operating performance. Maintaining roughly 10% net margins gives Virbac resources to support research, product development, commercial expansion, and resilience across the next several quarters.
Read all positive factors
Virbac SA (VIRP) vs. iShares MSCI France ETF (EWQ)
Market Cap
€2.58B
Dividend Yield0.48%
Average Volume (3M)3.49K
Price to Earnings (P/E)16.8
Beta (1Y)0.62
Revenue Growth4.82%
EPS Growth3.80%
CountryFR
Employees6,442
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)17.97
Shares Outstanding8,390,660
10 Day Avg. Volume3,954
30 Day Avg. Volume3,489
Financial Highlights & Ratios
PEG Ratio5.39
Price to Book (P/B)2.67
Price to Sales (P/S)2.05
P/FCF Ratio29.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€360.00Price Target Upside11.46% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)20.5
Revenue Forecast (FY)€1.55B
Virbac SA Business Overview & Revenue Model
Company Description
Founded in 1968 and based in Carros, France, Virbac S.A. is a prominent developer and distributor of a wide array of animal health products and services. The company's global operations extend across France, Europe, Latin America, North America, A...
How the Company Makes Money
Virbac makes money primarily by selling animal health products into the veterinary care and animal production ecosystems. Its revenue model is largely product-based: (1) Pharmaceuticals and therapeutic products: sales of prescription and over-the-...
Virbac SA Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
82
Very Positive
Cash Flow
63
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.46B | 1.40B | 1.25B | 1.22B | 1.06B |
| Gross Profit | 517.94M | 937.60M | 809.60M | 427.27M | 378.38M |
| EBITDA | 277.99M | 276.26M | 230.65M | 215.55M | 199.46M |
| Net Income | 150.89M | 145.29M | 121.30M | 121.97M | 113.16M |
Balance Sheet | |||||
| Total Assets | 1.91B | 1.85B | 1.46B | 1.36B | 1.22B |
| Cash, Cash Equivalents and Short-Term Investments | 122.50M | 149.63M | 175.91M | 177.38M | 172.79M |
| Total Debt | 288.83M | 307.01M | 120.11M | 96.86M | 95.37M |
| Total Liabilities | 789.18M | 805.12M | 545.81M | 521.17M | 498.84M |
| Stockholders Equity | 1.13B | 1.04B | 900.30M | 839.33M | 724.93M |
Cash Flow | |||||
| Free Cash Flow | 103.41M | 134.97M | 77.60M | 45.41M | 79.13M |
| Operating Cash Flow | 195.65M | 204.22M | 118.64M | 98.98M | 126.29M |
| Investing Cash Flow | -199.55M | -428.69M | -121.87M | -54.83M | -51.21M |
| Financing Cash Flow | -5.53M | 138.59M | -2.56M | -34.76M | -91.69M |
Virbac SA Technical Analysis
Negative
323.00
Price Trends
329.90
Negative
340.26
Negative
347.14
Negative
Market Momentum
-5.44
Positive
28.16
Positive
11.44
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:VIRP, the sentiment is Negative. The current price of 323 is below the 20-day moving average (MA) of 324.87, below the 50-day MA of 329.90, and below the 200-day MA of 347.14, indicating a bearish trend. The MACD of -5.44 indicates Positive momentum. The RSI at 28.16 is Positive, neither overbought nor oversold. The STOCH value of 11.44 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:VIRP.
Virbac SA Peers Comparison
UnderperformOutperform
Sector (55)
FR:VIRP
Virbac SA
302.00
-23.06
-7.10%
FR:ERF
Eurofins Scientific
70.92
7.67
12.12%
FR:VETO
VETOQUINOL
66.10
-5.92
-8.22%
Virbac SA Corporate Events
Virbac Updates Share Capital and Voting Rights Structure as of August 2026
Sep 7, 2026
Virbac SA reported that its share capital consists of 8,390,660 shares as of August 31, 2026, all listed on Euronext Paris. The disclosure also confirms a gross total of 12,705,412 voting rights and a net total of 12,696,376 voting rights after ex...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.